| Date Filed | Type | Description |
| 10/10/2023 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 08/25/2023 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders... |
| 08/16/2023 |
4
| Tripeny R Tony (Director) has filed a Form 4 on MESA LABORATORIES INC /CO/|
Txns:
| Exercised 1,105 options to buy
@ $0 |
|
| 08/16/2023 |
4
| Ladiwala Shiraz Shabanali (Director) has filed a Form 4 on MESA LABORATORIES INC /CO/|
Txns:
| Exercised 1,055 options to buy
@ $0 |
|
| 08/16/2023 |
4
| Sullivan John James (Director) has filed a Form 4 on MESA LABORATORIES INC /CO/|
Txns:
| Exercised 754 options to buy
@ $0 |
|
| 08/16/2023 |
4
| Alltoft Jennifer Sadie (Director) has filed a Form 4 on MESA LABORATORIES INC /CO/|
Txns:
| Exercised 754 options to buy
@ $0 |
|
| 08/16/2023 |
4
| Schmieder John Bradley (Director) has filed a Form 4 on MESA LABORATORIES INC /CO/|
Txns:
| Exercised 754 options to buy
@ $0 |
|
| 08/16/2023 |
4
| Hall Shannon (Director) has filed a Form 4 on MESA LABORATORIES INC /CO/|
Txns:
| Exercised 754 options to buy
@ $0 |
|
| 08/03/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/03/2023 |
8-K
| Quarterly results |
| 07/14/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 07/03/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 06/16/2023 |
4
| Sullivan John James (Director) has filed a Form 4 on MESA LABORATORIES INC /CO/|
Txns:
| Paid exercise price by delivering 6 shares
@ $134.45, valued at
$806.7
Exercised 15 options to buy
@ $0 |
|
| 06/16/2023 |
4
| Schmieder John Bradley (Director) has filed a Form 4 on MESA LABORATORIES INC /CO/|
Txns:
| Exercised 30 options to buy
@ $0 |
|
| 06/16/2023 |
4
| Owens Gary M (CEO) has filed a Form 4 on MESA LABORATORIES INC /CO/|
Txns:
| Paid exercise price by delivering 1,237 shares
@ $134.45, valued at
$166.3k
Exercised 500 options to buy
@ $0
Exercised 342 options to buy
@ $0
Exercised 819 options to buy
@ $0
Exercised 1,162 options to buy
@ $0 |
|
| 06/16/2023 |
4
| Archbold Brian David (SVP Operations) has filed a Form 4 on MESA LABORATORIES INC /CO/|
Txns:
| Paid exercise price by delivering 283 shares
@ $134.45, valued at
$38k
Exercised 35 options to buy
@ $0
Exercised 134 options to buy
@ $0
Exercised 178 options to buy
@ $0
Exercised 267 options to buy
@ $0 |
|
| 06/16/2023 |
4
| Sakys John (CFO) has filed a Form 4 on MESA LABORATORIES INC /CO/|
Txns:
| Paid exercise price by delivering 373 shares
@ $134.45, valued at
$50.1k
Exercised 196 options to buy
@ $0
Exercised 256 options to buy
@ $0
Exercised 396 options to buy
@ $0 |
|
| 05/25/2023 |
8-K
| Quarterly results |
| 05/08/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 03/27/2023 |
4
| Sakys John (CFO) has filed a Form 4 on MESA LABORATORIES INC /CO/|
Txns:
| Exercised 2,500 shares
@ $122.66, valued at
$306.7k
Sold 2,500 shares
@ $171.62, valued at
$429.1k
Exercised 1,000 shares
@ $122.66, valued at
$122.7k
Sold 1,000 shares
@ $167.01, valued at
$167k
Exercised 1,128 shares
@ $51.85, valued at
$58.5k
Sold 1,128 shares
@ $167.01, valued at
$188.4k
Exercised (in-or-at-the-money) 2,500 options to buy
@ $122.66, valued at
$306.7k
Exercised (in-or-at-the-money) 1,000 options to buy
@ $122.66, valued at
$122.7k
Exercised (in-or-at-the-money) 1,128 options to buy
@ $51.85, valued at
$58.5k
|
|
| 03/24/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 03/22/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 03/16/2023 |
4
| Sakys John (CFO) has filed a Form 4 on MESA LABORATORIES INC /CO/|
Txns:
| Exercised 1,000 shares
@ $70.56, valued at
$70.6k
Sold 1,000 shares
@ $165.71, valued at
$165.7k
Exercised (in-or-at-the-money) 1,000 options to buy
@ $70.56, valued at
$70.6k
|
|
| 03/15/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 03/13/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 03/09/2023 |
4
| Sakys John (CFO) has filed a Form 4 on MESA LABORATORIES INC /CO/|
Txns:
| Exercised 400 shares
@ $70.56, valued at
$28.2k
Sold 400 shares
@ $169.97, valued at
$68k
Exercised (in-or-at-the-money) 400 options to buy
@ $70.56, valued at
$28.2k
|
|
| 03/09/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 02/09/2023 |
4
| Sakys John (CFO) has filed a Form 4 on MESA LABORATORIES INC /CO/|
Txns:
| Exercised 1,000 shares
@ $51.85, valued at
$51.9k
Sold 1,000 shares
@ $184.27, valued at
$184.3k
Exercised (in-or-at-the-money) 1,000 options to buy
@ $51.85, valued at
$51.9k
|
|
| 02/06/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/06/2023 |
8-K
| Quarterly results |
| 02/06/2023 |
10-Q
| Quarterly Report for the period ended December 31, 2022 |
| 02/02/2023 |
SC 13G/A
| Invesco Ltd. reports a 4.4% stake in Mesa Laboratories Inc |
| 01/27/2023 |
SC 13G/A
| ROYCE & ASSOCIATES LP reports a 3% stake in Mesa Laboratories, Inc. |
| 01/26/2023 |
SC 13G/A
| BlackRock Inc. reports a 16.4% stake in MESA LABORATORIES INC |
|